FDA approves Opdivo and Cabometyx combo for advanced kidney cancer treatment
The U.S. Food and Drug Administration (FDA) has officially approved the combination of Bristol Myers Squibb's Opdivo (nivolumab) and Exelixis' Cabometyx (cabozantinib) for the first-line ... Read More
FDA approves BMS’ Opdivo, Yervoy combo for malignant pleural mesothelioma
Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line ... Read More
FDA approves Opdivo + Yervoy for HCC previously treated with sorafenib
Bristol Myers Squibb has secured approval for the combination of Opdivo (nivolumab) 1 mg/kg and Yervoy (ipilimumab) 3 mg/kg from the US Food and Drug ... Read More